Effect of beta2-agonist treatment and spirometry on exhaled nitric oxide in healthy children and children with asthma.
We set out to determine the effect of spirometry and bronchodilator therapy on exhaled nitric oxide (FE(NO)) values in children. We hypothesized that there will be no difference on FE(NO) values pre- and postspirometry and following bronchodilator therapy. Sixteen children [(mean = 14.4 +/- 1.2 years; range, 12-18 years; healthy controls (n = 6); asthmatics on inhaled steroids (n = 5); and asthmatics on no steroids (n = 5)] had exhaled nitric oxide (FE(NO)) measurements on 4 consecutive days as follows: pre- and postspirometry (day 1); pre- and postalbuterol metered dose inhaler (MDI) therapy (day 2); pre- and postspirometry and albuterol MDI therapy (day 3); and pre- and postspirometry and placebo MDI (day 4). FE(NO) was measured with a chemiluminescence analyzer, using the single vital capacity exhalation technique at an exhalation flow of 50 mL/sec. There were no statistically significant differences in FE(NO) values pre- and poststudy maneuvers under all experimental conditions in healthy children. However, in healthy children, clinically relevant (>10%) differences from baseline were observed on day 1 (3-18 min) and day 4 at 18 min. In children with asthma, FE(NO) values increased significantly by 11-19% from pretreatment levels at 8 and 18 min, postbronchodilator on day 2, and 12-17% at 8 and 18 min post bronchodilator and spirometry on day 3. Spirometry and treatment with a placebo (day 4) resulted in a decrease in FE(NO) values by 11% at 3 min postbaseline in patients on inhaled steroids. The changes observed were similar in children on vs. off inhaled steroids, and also in well-controlled vs. poorly controlled asthma. We conclude that FE(NO) values should be obtained consistently either pre- and at a specific time postalbuterol treatment or spirometry. Alternatively, changes in FE(NO) values should be interpreted in relationship to the timing of these maneuvers.
Kissoon
Niranjan
N
Department of Pediatrics, University of Florida Health Science Center/Jacksonville, Jacksonville, Florida 32207, USA. niranjan.kissoon@jax.ufl.edu
Duckworth
Laurie J
LJ
Blake
Kathryn V
KV
Murphy
Suzanne P
SP
Lima
John J
JJ
D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology*; D001944:Breath Tests; D002648:Child; D006801:Humans; D008163:Luminescent Measurements; D036501:Metered Dose Inhalers; D009569:Nitric Oxide / Q000032:analysis*; D013147:Spirometry
D000318:Adrenergic beta-Agonists; D009569:Nitric Oxide; D000420:Albuterol